ZyCoV-D is deposited under the skin, as opposed to deep in muscle tissue. The area under the skin is rich in immune cells that gobble up foreign objects, such as vaccine particles, and process them. This helps capture the DNA far more efficiently than in the muscle. Unusually, the vaccine is delivered using a needle-free device known as PharmaJet needle-free applicator pressed against the skin, which creates a fine, high-pressure stream of fluid that punctures the surface and ensures "painless intradermal vaccine delivery".
Despite being more potent than previous DNA vaccines, ZyCoV-D requires a minimum of three doses to achieve its initial efficacy. This is likely to add to the logistical challenge of administering the vaccine during the current pandemic.
The ZyCoV-D trials in India earlier this year were conducted while the Delta variant of SARS-CoV-2 was the dominant variant in peak circulation whereas earlier mRNA vaccine trials were conducted when less transmissible variants were circulating. The efficacy is essentially pretty good against the Delta variant.
ZyCoV-D Plasmid DNA vaccine is developed by Indian pharmaceutical firm Cadila Healthcare Ltd., headquartered in Ahmedabad. On 20 August 2021, India’s drug regulator authorized the vaccine for people aged 12 and older. The efficacy figure of 66.6% came from trials involving more than 28,000 participants, which saw 21 symptomatic covid cases in the vaccinated group and 60 among people who received a placebo.
The submission for EUA was done on 1 July 2021.
ZyCoV-D contains circular strands of DNA known as plasmids, which encode the covi spike protein, together with a promoter sequence for turning the gene on. Once the plasmids enter the nuclei of cells, they are converted into mRNA, which travels to the main body of the cell, the cytoplasm, and is translated into the spike protein itself. The body’s immune system then mounts a response against the protein, and produces tailored immune cells that can clear future infections. Plasmids typically degrade within weeks to months but the immunity remains.
Cadila Healthcare Ltd. revealed that developing the DNA vaccine and delivering the vaccine injection-free aims to reduce significantly any kind of side effects. The plasmid DNA platform provides ease of manufacturing with BSL-1 biosafety level requirements. The vaccine has no problem associated with vector based immunity.
News (2)
4 kinds of ZyCoV-D vaccine administration during clinical trial and their results
According to the Indian study published by The Lancet, Zydus Cadila's Phase III clinical trial shows the following seroconversion rate results based on 1 mg of ZyCoV-D injection, 1 mg of ZyCoV-D needle-free vaccine administration, 2 mg of ZyCoV-D injection and 2 mg of ZyCoV-D needle-free vaccine administration on the 28th day, 56th day and 84th day of the three-dose regimen. The significant seroconversion rate results on the 84th day are as follows:-
84 days after 1 mg of ZyCoV-D injection administration, seroconversion rate of 36% is achieved.84 days after 1 mg of ZyCoV-D deposited under the skin achieves seroconversion rate of 33%.
84 days after 2 mg of ZyCoV-D jab achieves seroconversion rate of 100%.
84 days after 2 mg of ZyCoV-D deposited under the skin, seroconversion rate of 80% is achieved.
Seroconversion is defined as antibody negative subjects at baseline who have become antibody positive after vaccination and subjects having antibody titre at baseline who have four-fold rise in antibody titre after vaccination.
Cadila Healthcare Ltd. did not reveal why it did not introduce the DNA vaccine injection despite it achieving 100% seroconversion rate on the 84th day after the first injection dose of ZyCoV-D during the clinical trial.
Observers believe that the injection-free covi vaccine aims to encourage people fearful of mRNA vaccine injection into their muscles to get vaccinated under their skin and it is a painless vaccine.
News (3)
Yet to seek approval for two dose of ZyCoV-D regimen
Cadila Healthcare Ltd. reveals that it plans to seek approval for the two dose of the DNA vaccine regimen.
The main advantage of its DNA vaccines is their ability to stimulate both the humoral and cellular arms of the adaptive immune system. The vaccines are safe and stable.
Refs: https://www.nature.com/articles/d41586-021-02385-x, https://www.epochtimes.com/gb/21/10/9/n13292766.htm, https://www.zyduscadila.com/public/pdf/pressrelease/ZyCoV_D_Press_Release_1_7_2021.pdf, https://www.zyduscadila.com/public/pdf/pressrelease/Press%20Release-Zydus-receives-EUA-from-DCGI-for-ZyCoV-D.pdf,
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00300-X/fulltext
News (4)
Expert: Merck covid oral pills could pose serious health risks
Image credit : Merck. Copyright © 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved.)
The U.S. pharmaceutical giant Merck is experimenting oral drug molnupiravir for the treatment of COVID-19 (covid, in short). Many people regard it as a "magic bullet" to deal with the pandemic. However, some scientists warned that the drug has serious health risks, and it is necessary to "act with caution". Otherwise people will be at their own risk.
According to a report published in the US "Barron's" magazine on Thursday (7 October 2021), some scientists who have studied molnupiravir believe that the drug's method of suppressing the virus has potential risks and may limit the drug utility.
The working principle of molnupiravir is to integrate itself into the genetic material of SARS-CoV-2 (covi), and then cause a large number of mutations during the covi replication process, thereby effectively killing the virus.
However, in some laboratory tests, molnupiravir also showed the ability to be incorporated into the genetic material of mammalian cells and cause mutations when these cells replicate. If this happens to the cells of patients treated with molnupiravir, it could theoretically lead to cancer cells or lead to birth defects.
Raymond Schinazi, professor of pediatrics and director of biochemical pharmacology at Emory University, an elite private university in the United States, studied molnupiravir and published many papers on NHC, which is one of the active drug ingredients.
In a paper published by Hinaz, molnupiravir can produce similar reactions as mentioned above. He insisted that without more data, it should not be given to young people, especially pregnant women or childbearing age.
According to the federal government website that tracks clinical trials, the Molnupiravir trial conducted by Merck does not include pregnant women and the scientists in charge of the trial asked male participants to prohibit sex while taking the drug.
"Barron's" also shared a paper published in May in The Journal of Infectious Diseases (JID) by Professor Hinatz and University of North Carolina scientists. The paper reports that in a laboratory test designed to detect mutations in animal cells, NHC can cause mutations in animal cells.
Hinatz, who has studied the NHC for decades, wrote in an email to Barron’s, “Proceed with caution and at your own risk.”
It is not just Professor Hinatz who is issuing a warning. Many scientists and doctors who have studied the NHC say that Merck needs to be "careful."
Dr. Shuntai Zhou, a scientist at the Swanstrom Lab at the University of North Carolina at Chapel Hill (UNC), said, “People are worried that this will cause long-term mutational effects and even cancer.”
Dr. Zhou added, “Biochemistry does not lie.” He is sure that the drug molnupiravir will integrate itself into the DNA of the mammalian host.
At present, Merck has not released any data on animal studies of molnupiravir but scientists believe that long-term studies are needed to prove that this drug is truly safe.
News (5)
Early safety concerns accompanied molnupiravir
Source : Brian Buntz, Drug Discovery & Development
The antiviral molnupiravir appears to be destined to become the first oral treatment for covid. Merck and its partner Ridgeback Biotherapeutics intend to file for emergency use authorization after announcing that the drug appears to reduce the risk of hospitalization or death by about 50%.
One potential hurdle for the drug is whether unvaccinated individuals will accept the treatment, given their higher likelihood of contracting severe covid. According to McKinsey, unvaccinated individuals tend to be most concerned about the potential of covivaccines to cause long-term side effects.
The lack of long-term safety data concerning molnupiravir could be an obstacle for skeptical patients. That’s especially the case given early conclusions that there are “persistent side-effect concerns with mutagenic molnupiravir,” as a Clinical Trials Arena article observed. That article goes on to cite Ron Swanstrom, a professor at the University of North Carolina, Chapel Hill, who in January questioned “whether molnupiravir could be metabolized into a precursor of DNA,” and then “enter the host cell nucleus, leading to oncogenesis.”
In theory, mutagenic drugs can cause either birth defects or cancer. The inclusion criteria for the Phase 3 study of molnupiravir required males to refrain from donating sperm and either agree to abstain from sex or use contraception. Females were required to not be pregnant or breastfeeding. Women who were of child-bearing age had to agree to use a highly effective contraceptive method or be abstinent for 28 days from the start of the study intervention. In addition, women of childbearing age must have had a negative highly sensitive pregnancy test within 24 hours before receiving the first dose of medicine.
Merck did not immediately respond to a request for comment. However, in a conference call last week, Merck virologist Daria Hazuda stressed that Merck had seen “no evidence of the potential for mutagenicity” for this agent. She concluded that the company is “very comfortable that the drug will be safe if used as intended.”
Molnupiravir is a prodrug of nucleoside analogue β-D-N4-hydroxycytidine (NHC), which could potentially be incorporated in mammalian DNA.
One study determined there was evidence that the drug could potentially drive mutagenesis in both viral RNA and mammalian DNA. “It seems unlikely that a short course of therapy would spare the host from this exposure because both RNA precursors that affect the virus and DNA precursors that would affect the host pass through the common ribonucleoside diphosphate intermediate,” concludes an article in the Journal of Infectious Diseases.
SVB Leerink analyst Dr. Geoffrey Porges predicts that FDA would restrict who has access to the drug over safety concerns, according to Barron’s.
In the Phase 3 trial of the drug, the side effects of COVID-19 are apparently worse than that of molnupiravir as patients in the placebo group were more likely to withdraw early than recipients of the drug.
An August article published in the Journal of Infectious Diseases found that β-D-N4-hydroxycytidine (NHC, initial metabolite of molnupiravir) “displays host mutational activity in an animal cell culture assay, consistent with RNA and DNA precursors sharing a common intermediate of a ribonucleoside diphosphate. These results indicate highly active mutagenic ribonucleosides may hold risk for the host.”
In 2020, the former Head of U.S. Biomedical Advanced Research and Development Authority (BARDA) Rick Bright opposed granting additional funding to develop the drug, partly over safety concerns related to the drug. In a complaint summarized in Science, Bright wrote that “similar experimental drugs in this class had been shown to cause reproductive toxicity in animals, and offspring from treated animals had been born without teeth and without parts of their skulls.”
The Science article also quotes the Emory University chemist Raymond Schinazi who stated that his previous pharmaceutical company, Pharmasset, abandoned a similar drug in 2003 after discovering its mutagenic properties.
Scientists at Emory University’s Drug Innovation Ventures at Emory (DRIVE) report seeing no evidence of mutagenicity.
In April, Merck announced that it had performed extensive nonclinical research to characterize the safety profile of molnupiravir. “This program included assays such as Big Blue and PIG-a, which are designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo,” the company said. “Animals were administered molnupiravir for longer and at higher doses (mg/Kg) than those employed in human studies.” The company concluded that the data from the studies indicate that molnupiravir is not “mutagenic or genotoxic in vivo mammalian systems.”
The first-in-human Phase 1 study also confirmed molnupiravir’s safety profile. There were no serious adverse events among monlupiravir recipients. In addition, fewer than half of those who received the drug reported an adverse event. Among those who did, 93.3% were mild, according to an article published in Antimicrobial Agents and Chemotherapy.
There was also no evidence of accumulation of the drug in the study, the report authors wrote.
It is also worth noting that molnupiravir will likely be used on a short-term basis, which will likely limit adverse events.
“Molnupiravir demonstrated good tolerability and dose-proportional pharmacokinetics following administration to healthy volunteers at clinically relevant doses is well-positioned to be evaluated for clinical efficacy and safety in large-scale COVID-19 studies,” the report authors concluded.
News (6)
Merck asks FDA for EUA of molnupiravir
Reporter : Mary Kekatos, Daily Mail
Molnupiravir is an antiviral drug that was developed at Emory University, in Atlanta, by its drug innovation company, Drug Innovation Ventures at Emory (DRIVE), which was licensed by Ridgeback Biotherapeutics LP, who partnered with Merck.
It was originally meant to treat influenza and prevents the virus from making copies of itself by creating errors during viral RNA replication.
Animal studies conducted last year found molnupiravir could completely suppress viral transmission and prevent and reduce severe lung damage.
The new study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe illness due to health problems such as obesity, diabetes or heart disease.
Among patients taking molnupiravir, 7.3 percent were either hospitalized or died at the end of 30 days, compared with 14.1 percent of those getting the dummy pill.
There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck.
The results were released by the company and have not been peer-reviewed, but Merck says it plans to present them at a future medical meeting.
An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong.
'It exceeded what I thought the drug might be able to do in this clinical trial,' Dr Dean Li, vice president of Merck research, told the Associated Press.
'When you see a 50 percent reduction in hospitalization or death, that's a substantial clinical impact.'
Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.
Ref: https://www.dailymail.co.uk/health/article-10079873/Merck-seeks-U-S-FDA-authorization-COVID-19-tablet.html
News (7)
AstraZeneca announces test results of its antibody drug AZD7442 therapy
Image : Reuters
AstraZeneca, a British pharmaceutical company, issued a statement on 11 October 2021 that its covi antibody drug AZD7442 therapy is in an advanced trial. The results show that it can reduce the risk of deterioration and death of mild to moderate patients by 50%.
Bloomberg and Reuters reported that the study was conducted on a total of 822 patients in the United Kingdom, Brazil, the United States, and Germany who had symptoms of covid for less than 7 days (inclusive) but were not hospitalized. It was found that the antibody drug AZD7442 therapy was used. Of the patients, 18 had worsened conditions; 37 of those who used placebo had worsened conditions. In other words, AZD7442 can reduce the risk of severe illness or death by 50%, and this result is consistent with the main goal of the trial.
Mene Pangalos, executive vice president of the biopharmaceutical research and development department of the pharmaceutical company, said, "Early intervention of antibody drugs can significantly reduce the chance of severe illness, and the protection lasts for more than 6 months." It is understood that the vaccine is mainly through the vaccinators. The immune system produces antibodies and anti-infective cells to fight the virus; the antibody drug AZD7442 therapy uses laboratory-made antibodies. These antibodies can stay in the body for several months to protect people from infection.
Previous trials have confirmed that AZD7442 therapy is very effective in preventing symptomatic infections in high-risk populations, and the results this time are even more beneficial. AstraZeneca has recently submitted an emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA).
The report pointed out that antibody therapy is one of the main channels for fighting covid, and it can be used as an alternative therapy for people with poor immune response after vaccination or unable to produce immunity. Suitable groups for antibody therapy include cancer patients or people with weakened immune systems.
The main researcher of the trial, University College London (UCL) Critical Care Professor Hugh Montgomery, said, "With the continuous increase of severely ill patients worldwide, new therapies such as AZD7442 are in great demand, which can be used to protect the fragile ethnic group."
The results of another trial for patients within 5 days of onset of symptoms showed that AZD7442 therapy can reduce the chance of getting worse by 67%. Ninety percent of the tested patients are considered to be at high risk of severe illness, including patients with diabetes and cancer.
News (8)
Image : The Fantasia Holdings Group, founded by Zeng Qinghong's niece Zeng Baobao, has a debt of 83 billion yuan. An announcement was issued on 4 October that the debt of approximately US$206 million that was due that day had not been repaid. The picture shows the profile photos of Zeng Baobao and Zeng Qinghong. (Epoch Times composite picture)
The Fantasia Holding Group founded by Zeng Qinghong's niece Zeng Baobao is in financial crisis. Zeng Baobao recently issued a series of articles stating that "the butt determines the decision of the head" and "the Fantasia will never lie flat". According to expert analysis, Zeng Baobao's remarks are suspected of provoking Xi Jinping.
Following Evergrande, another Chinese real estate developer Fantasia Holdings Group also broke out in a financial crisis. On 4 October 2021, Fantasia failed to pay a maturity of US$206 million in bonds.
That night, Zeng Baobao, the actual controller of Fantasia, posted a screenshot of the movie poster of "Darkest Hour" on Weibo.
On the 6th, she posted a set of pictures of Monkey King on Weibo, with the texts "Look at my bright strokes", "Open the road in the mountains", and "Dare to fight."
On the 7th, Zeng Baobao once again posted, “Professional matters are left to the professionals, the ass decides the decision-making of the head, and the one with the best ass sits, and the others are babbling, thank you. Focus".
This post seems to have an overtone. According to Chen Youcheng, a Chinese financial scholar, Zeng Baobao said, "Give it to the one who sits on the bottom", "It clearly shows that her backer seems to be unreliable. Now only Xi Jinping is in the 19th and 10th National Congress of the Communist Party of China. The faction in power after the Eighth National Congress of the Communist Party of China, then their ass and backing are the most stable."
At night of the 8th, Zeng Baobao’s office sent a letter to the employees by e-mail, saying that “the Fantasia will never lie down”. The company has set up a special team to try to get out of the predicament, but the problem has not yet been resolved.
According to the report for the first half of 2021, Fantasia’s total liabilities were RMB 83.007 billion, and the net debt ratio was 74.8%. The short-term liabilities due within one year were RMB 19.545 billion, and the debt-to-asset ratio was 75.7%.
Tang Jingyuan, a current affairs commentator in the United States, told NTD that the difficulty of borrowing and financing currently encountered by Fantasia is closely related to Xi Jinping's current reorganization of real estate companies.
"Zeng Baobao can't borrow money from the mainland bank anymore. She posted a post obviously insinuating Xi Jinping." Tang Jingyuan said, "In Zeng Baobao's eyes, this is a decision made by the ass to determine the head, because this blocked her muffled voice. Make a fortune."
Fantasia was established in 1996 and was listed in Hong Kong in November 2009. In 2010, it became one of the top 50 real estate companies in China. However, since Xi Jinping came to power in 2012, Fantasia's sales have been at a low level for 5 consecutive years.
In 2019, Zeng Baobao, who retired from behind the scenes, returned to the front of the scene as CEO of the real estate group, but she still failed to restore the downward trend.
Public information shows that there are currently 12 US dollar bonds coexisting in Fantasia, with a debt balance of 3.98 billion US dollars. Five of them will expire within one year, totaling US$1.559 billion; three will expire in 2021, totaling US$762 million. The interest rates of these US dollar bonds are generally high, with 7 having an interest rate higher than 10%, with a maximum of 15%; and only 3 having an interest rate lower than 8%.
Recently, the ratings of the three major international rating agencies, Standard & Poor's, Fitch, and Moody's, have all downgraded the ratings of Fantasia to “negative”. Fitch estimates that between now and the end of next year, Fantasia will have to repay nearly US$2 billion in international bonds and nearly US$1 billion in local market bonds.
Chen Youcheng, a Chinese financial scholar, believes that Zeng Baobao's lack of beauty nowadays is because her patron has become the target of attacks in political power struggles. On the contrary, a real estate company that is not regarded as a hostile force by those in power can "escape."
Chen Youcheng said, "The family powers of Jiang Zemin, Li Peng, and Zeng Qinghong that Xi Jinping wants to fight against will finally remove them from the political influence by first investigating their economic problems, especially their investment and holdings in various fields in China."
Epoch Times columnist Wang He told NTD that at present, the economic strength of the Zeng Qinghong family and the expansion of the field are quite deep and the net is quite large. "Baby Zeng may just be a signal."
News (11)
U.S. release of Marine Corps stationed in Taiwan spurs CCP military threat
Image : The Republic of China military power display at 10.10 Taiwan National Day Parade (Video Screenshot)
Just after the CCP military planes disrupted Taiwan on a large scale, the United States revealed to the media that there is a special operations force in Taiwan to assist Taiwan’s defense. British media "Times" analyzed that U.S. troops stationed in Taiwan is not a secret, the timing of exposure is the point.
On 8 October 2021, the Wall Street Journal quoted an unnamed U.S. official as saying that a U.S. special operations force and a Marine Corps, about 20 people, have trained the local army in Taiwan for at least one year.
In 2018, when the new building of the American Association in Taiwan (AIT) Taipei Office (AIT) opened, the former US Consul General in Hong Kong, Yang Sudi, disclosed that the new building will be dispatched by a detachment of the "U.S. Marine Corps Embassy Guard" to be responsible for security.
Lu Zhengfeng, an associate professor in the Department of International and Mainland Affairs at Golden Gate University in Taiwan, revealed that in addition to protecting the embassy's Marine Corps stationed in Taiwan, the United States has many arms sales to Taiwan, and related weapons and personnel training are normal military exchanges.
Lu Zhengfeng, associate professor of the Department of International and Mainland Affairs at Golden Gate University, said, “The disclosure of this information basically tells the Chinese Communist authorities and reminds them that, in fact, Taiwan and the United States have always existed in military cooperation, which has a deterrent effect.”
At the beginning of October, the CCP has repeatedly disrupted Taiwan with record-breaking military aircraft. "Times" pointed out that at this time, U.S. officials released the news that US troops were stationed in Taiwan and expressed their intention to openly support Taiwan.
Current affairs commentator Tang Jingyuan said, “The main reason behind this is that the CCP’s threat in the Taiwan Strait is obviously escalating, and it is becoming more and more inclined to develop in actual combat. Therefore, the U.S. warning and correspondingly increased reciprocal measures show that the U.S. has more or less stopped worrying about the CCP’s reaction."
Lu Zhengfeng believes that in addition to the warming of U.S.-Taiwan military interaction, the United States is accelerating its decoupling from the CCP’s high-tech technology, highlighting Taiwan’s key position in the peninsula’s supply chain.
News (12)
Studying in Taiwan to experience democracy Little Pink thought change: I love Taiwan
Image : A video was circulated on Twitter. A Chinese student reported that after studying in Taiwan, he changed from a little pink to a normal person. (Tweet video screenshot)
On 9 October 2021, Twitter user "News/Truth" uploaded a video in which a mainland student awakened after studying in Taiwan and turned from a little pink to a normal person. .
Five years ago, he went to Taiwan by chance. A few years later, he even spoke with a Taiwanese accent.
He said in the video, "I am very grateful for that opportunity, because if I don't go to Taiwan, I don't know what Taiwan and other countries are like. Of course I also hate going to Taiwan this time because I went to Taiwan. After that, sometimes you can compare what the government has done. What other people can do, you, as a powerful country (China), you can’t do. And when you say it, you are not allowed to say, this is the sorrow of a powerful country."
He stated that when he first came to Taiwan, "I was really in a state of ignorance, because I have never seen so many parades, people can come out and stand on the street. I have never been in my 20s. I haven't seen it before. My impression of Taiwan before was stuck in traditional Chinese characters, the accent of Taiwanese Mandarin."
What shocked him even more was, "President, President Tsai, Tsai Ing-wen, you can scold her and call her by her first name. You can scold Ma Ying-jeou, and you can even dismiss the mayor."
He said sincerely, "Taiwan has changed my original little pink identity and got into trouble for this, but I never regret it because I am no longer the one I used to be. I am not the sleeping majority. I think people live worthwhile."
When he returned to mainland China, his biggest feeling was that social media such as Facebook could not be used anymore. The feeling of returning to the wall was not very good: "At that time, when I returned to China from Taiwan, I just got off the plane. Say, oh, I’m back, because I can’t upload everything on Facebook, Instagram, or Twitter. Now China is becoming less and less dare to say..."
In the end, he concluded with one sentence, "I love Taiwan."
Some analysts say that they know why the mainland's Ministry of Education has suspended the plan for mainland students to study in Taiwan in 2020.
News (13)
Japanese scholar analyzed once "dovish" Fumio Kishida's strategy for China
After Fumio Kishida became the new prime minister of Japan, the outside world is concerned about how his diplomatic strategy and China line will unfold. A Japanese scholar who studies the Asia-Pacific situation pointed out that Kishida, who was previously regarded as a "dovish" figure of the Liberal Democratic Party (Liberal Democratic Party), will work to make Japan an important balancing force in the Asia-Pacific region, and being tough on China is an inevitable choice.
After Fumio Kishida formally assumed the post of Japan’s 100th Cabinet Prime Minister (Prime Minister) on October 4, he once stated at a press conference that he would “tell them what he should say” when facing the Chinese Communist authorities in the future. The outside world is concerned about what Kishida will "should say" in terms of CCP policy.
In an interview with Deutsche Welle, a professor of Asian and Pacific Studies at Waseda University, Japan, David Leheny said that Japan’s parliamentary elections are coming soon. After Kishida became Japanese prime minister, he first issued his message to conservative voters of the Liberal Democratic Party. A signal to take a hard line towards the CCP.
Renee analysis pointed out that in terms of diplomacy, Kishida not only tried to express his basic position to China (the Chinese Communist Party), but also tried to express to the United States, Southeast Asian countries and Taiwan that he would be committed to making Japan a leader in the Asia-Pacific region during his tenure as prime minister of Japan, an "Important balancing power."
In the past, when Kishida followed Abe to participate in government affairs, he was once regarded as a "dove" by the outside world. In this regard, Rennie said that no matter how deep Kishida’s past commitments to the real “dovists” are, his previous experience as Minister of Foreign Affairs is likely to prompt him to come to a conclusion-“Reconciliation with China (the Chinese Communist Party) is only and will be counterproductive."
Regarding the establishment of the "Minister of Economic Security" in the new cabinet by Fumio Kishida and the important task of Takayuki Kobayashi, who joined the cabinet for the first time, Rennie said that Kobayashi has served as a financial policy bureaucrat in the past and participated in many investment projects. He has real experience. Rich. Now he needs to elevate media hot topics such as building semiconductor supply chains and preventing technology outflows into substantive policy debates.
Rennie said, "Japan's economic health has long depended on its global connections, but this can also lead to vulnerabilities. It is indeed beneficial for him to systematically calculate these vulnerabilities and develop hedging strategies."
The Chinese Communist government and the Taiwanese government have already submitted applications to join the CPTPP in mid-to-late September, and Fumio Kishida has publicly expressed his support for Taiwan's participation in the TPP before. As for how Kishida will treat the application of the Chinese Communist government, Rennie believes that Kishida will not rush to allow CCP China to join the CPTPP, and Australia and other CPTPP member states will not allow it to do so.
Rennie said that there are too many potential factors for whether CCP China can join the CPTPP, including the ambiguity of trade restrictions, the opacity of data, and so on. All in all, it is really difficult for the Chinese Communist government to join the CPTPP in a short period of time.
Renee believes that Kishida will very much hope that the United States will return to the CPTPP, because this can further balance the CCP's influence in regional affairs. He said frankly that Kishida must find ways to get the United States to rekindle the goodwill of CPTPP. "If the United States shows interest, this must be the easiest way for Kishida to promote (CPTPP)."
News (14)
In Tsai Ing-wen’s National Day speech “No Mainland”, the CCP media screamed “unprecedented arrogance”
President Tsai Ing-wen put forward the "four persistences" in his National Day speech on 10 October 2021, insisting that the Republic of China and the People's Republic of China are not affiliated with each other. The CCP media Global Times published a commentary and criticized Tsai Ing-wen's talk for "one country on one side". Only menntioning "China" (without Mainland) has an unprecedented arrogant attitude; DPP legislator Lai Ruilong said in an interview today that China should stop deceiving itself and should face up to the existence of the Republic of China. President Tsai is only telling the truth.
President Tsai Ing-wen’s speech on the National Day put forward “upholding a free and democratic constitutional system”, “upholding the non-subordination of the Republic of China and the People’s Republic of China”, “upholding the inviolability and annexation of sovereignty”, and “upholding the future of Taiwan of the Republic of China, and we must follow all Taiwanese people. The four insistences such as "the will" emphasize that this is the bottom line given to us by the people of Taiwan, and it is also the greatest common divisor.
The Global Times commented on the content of Tsai Ing-wen's speech using words such as "sensational language" and "deception". This time it only called "China", and the absence of "Mainland" means "unprecedented arrogant attitude."
Regarding the Global Times editorial, DPP legislator Lai Ruilong said, "President Tsai's statement is to tell the truth!" In anti-criticism, it is China that is destroying cross-strait relations from beginning to end, and China is constantly erasing the fact that the Republic of China exists. CCP lies internationally that there is only one China.
Mainland Affairs Council spokesperson Qiu Chuizheng said today that President Tsai’s National Day remarks demonstrated the consistency of cross-strait policies, conveyed the firm determination and will of the 23 million people in Taiwan, and called on the Beijing authorities to abandon the enemy’s will and use force to resolve disputes. The Republic of China’s sovereignty must not be allowed. Any malicious slander and provocation is not accepted.
Qiu Chuizheng pointed out that the Republic of China is a sovereign and independent country that has stood unshakable for 110 years. There is no subordinate relationship between the two sides of the Taiwan Strait. This is a fact. As the Beijing authorities continue to proclaim the unification of Taiwan, and intensified their recent efforts to destroy the status quo across the Taiwan Strait, in an attempt to eliminate the Republic of China, we must solemnly declare that the 23 million people in Taiwan will unite and defend our country’s sovereignty and dignity.
News (15)
The Chinese Communist Party is plagiarizing history yet the Kuomintang sings along
Image : Executive Yuan Principal Su Zhenchang attended the meeting of the Legislative Yuan and accepted a joint media interview before the meeting. (Photo by reporter Wang Yisong)
Regarding President Tsai Ing-wen’s October National Day speech, Executive Yuan Su Zhenchang on 12 October 2021 said that President Tsai’s remarks are facts and are in line with the status quo. The people in Taiwan should unite with the outside world. Referencing the deer as a horse, plagiarizing history, Kuomintang dare not respond, and sings with the Chinese Communist Party (CCP), which is deeply worthless.
Su Zhenchang went to the Legislative Yuan today to conduct a policy and address questions. Regarding President Tsai’s October National Day speech, it was interpreted as a two-state theory and caused a backlash in China. Su Kui interviewed before entering the forum and said that President Tsai’s speech was factual and consistent with the status quo.
Su Kui pointed out that China not only wants to invade and annex Taiwan but even the history of the Revolution of 1911, the fact that it has never ruled Taiwan, and even the mainstream values of the world should respect public opinion but CCP is not abiding by it, and is undermining regional peace.
Su Kui also emphasized that the people of the Chinese people in Taiwan should be united with the outside world. The Chinese Kuomintang was accused by the CCP and the People's Republic of China for plagiarizing history. It dared not respond but it still sang along, which is deeply worthless.
No comments:
Post a Comment